|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||45.92 - 45.92|
|52 Week Range||45.92 - 79.91|
|Beta (5Y Monthly)||0.90|
|PE Ratio (TTM)||16.46|
|Forward Dividend & Yield||1.41 (3.07%)|
|Ex-Dividend Date||May 13, 2022|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for FMCQF
Fresenius Medical Care (NYSE: FMS; Frankfurt Stock Exchange: FME) and CytoSorbents Corporation (NASDAQ: CTSO) have expanded their partnership by establishing a multi-stage global collaboration to combat life-threatening diseases in critical care for an initial term of three years. The new agreement provides for the combined marketing and promotion of CytoSorb® with Fresenius Medical Care's critical care products by Fresenius Medical Care's marketing organization worldwide, excluding the United S
Fresenius Medical Care North America's (FMCNA) Renal Therapies Group today announced the availability of the CombiSet SMARTECHTM, the first available single-use bloodline with an integrated Crit-Line® blood chamber (CLiC™) that simplifies use by reducing the number of manual connections required. The CLICTM Blood Chamber is built into the bloodline itself and is designed to provide optimal performance with the 2008® series hemodialysis machines.
HONG KONG, May 12, 2022--Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, today announced its global ‘United in Care’ campaign that celebrates the diversity, unity and positive impact of its nurses and clinical teams across Asia Pacific, Europe, the Middle East and Africa, North America and Latin America.